Evidence map›Paper›PMID 41452898›Full record

ArticlePloS one2025

In-silico core proteome analysis for chimeric vaccine development against tick-borne tularemia.

Bader S Alotaibi, Fatiha Khan, Muhammad Bilal Iqbal Rehmani, Fizza Arshad, Muhammad Umer Khan, Umar Nishan, Abid Ali, Khaled Fahmi Fawy, Sarah A Altwaim, Saeed M N Alasmari and 2 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bader S AlotaibiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Al- Quwayiyah, Shaqra University, Riyadh, Saudi Arabia.
Fatiha KhanDepartment of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Muhammad Bilal Iqbal RehmaniDepartment of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Fizza ArshadDepartment of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Muhammad Umer KhanInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Umar NishanDepartment of Chemistry, Kohat University of Science and Technology, Kohat, Pakistan.
Abid AliDepartment of Zoology, Abdul Wali Khan University Mardan, Mardan, Pakistan.
Khaled Fahmi FawyDepartment of Chemistry, Faculty of Science, Research Center for Advanced Materials Science (RCAMS), King Khalid University, Abha, Saudi Arabia.
Sarah A AltwaimDepartment of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Saeed M N AlasmariDepartment of Biology, Faculty of Science and Arts, Najran University, Najran, Saudi Arabia.
Hanna DibCollege of Engineering and Technology, American University of the Middle East, Kuwait.
Mohibullah ShahDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Al- Quwayiyah, Shaqra University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0001-6126-7102

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tularemia is an extremely contagious zoonotic illness resulting from infection with the intracellular bacterium Francisella tularensis. It is transmitted primarily via vector bites particularly from ticks, flies, and mosquitoes and is a severe public health threat. Because of its high virulence, low infective dose, aerosol transmissibility, and potential for mass casualties, F. tularensis is also considered a potential biological warfare agent. Despite its severity, there is presently no licensed vaccine against this pathogen. In the present work, a subtractive proteomics pipeline was implemented to identify potential antigenic targets to prepare a multi-epitope vaccine. Five vaccine constructs were generated through the combination of B-cell, HTL, and CTL epitopes with suitable adjuvants and linkers. Among these, two constructs V1 and V2 were extremely non-allergenic and antigenic. To assess immune receptor engagement, molecular docking was conducted with TLR4 and TLR5, followed by 200 ns molecular dynamics simulations. Vaccine-receptor complexes were analyzed using RMSD, RMSF, radius of gyration (Rg), Dynamic Cross-Correlation Matrix (DCCM), SASA, PCA, H-bond analysis and MMPBSA binding energy calculations, all confirming structural stability and strong binding affinity. In-silico cloning revealed a GC content of 50% and 1.0 codon adaptation index (CAI), suggesting high expression potential in E. coli. Immune simulation further supported the construct`s ability to elicit a robust and long-lasting immunity. These computational findings highlight the potential of the constructed vaccines as effective candidates against F. tularensis, though experimental substantiation is requisite.

Indexed as

Bacterial VaccinesFrancisella tularensisProteomeTick-Borne DiseasesTularemiaVaccine DevelopmentAnimalsEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansMolecular Docking SimulationMolecular Dynamics SimulationProteomicsTicksBacterial VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteProteome

Identifiers

PMID41452898
PMCPMC12742777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.